Pembrolizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pembrolizumab" in English language version.

refsWebsite

Global rank English rank

67web.archive.org

1^st place

36nih.gov

4^th place

31fda.gov

447^th place

338^th place

22doi.org

2^nd place

5tga.gov.au

3,984^th place

2,622^nd place

4clinicaltrials.gov

5,225^th place

4,062^nd place

3europa.eu

68^th place

117^th place

3semanticscholar.org

11^th place

8^th place

2drugs.com

399^th place

333^rd place

2medicines.org.uk

3,823^rd place

2,387^th place

2cancer.gov

1,684^th place

1,350^th place

2harvard.edu

18^th place

17^th place

2forbes.com

54^th place

48^th place

2thepharmaletter.com

low place

2archive-it.org

910^th place

593^rd place

2onclive.com

low place

1hpfb-dgpsa.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1handle.net

102^nd place

76^th place

1ama-assn.org

3,257^th place

3,398^th place

1thetranslationalscientist.com

low place

1inventorsdigest.com

low place

1cancernetwork.com

low place

1nytimes.com

7^th place

1merck.com

6,464^th place

5,671^st place

1nature.com

234^th place

397^th place

1asco.org

low place

1fiercepharma.com

low place

8,921^st place

1england.nhs.uk

low place

1bbc.co.uk

8^th place

10^th place

1telegraph.co.uk

30^th place

24^th place

1managedcaremag.com

low place

1medpagetoday.com

9,274^th place

5,856^th place

1neoleukin.com

low place

ama-assn.org

searchusan.ama-assn.org

"Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). AMA ASSN. 27 November 2013. Archived (PDF) from the original on 26 October 2020. Retrieved 5 November 2016.

archive-it.org

wayback.archive-it.org

"Pembrolizumab injection". U.S. Food and Drug Administration. 5 October 2015. Archived from the original on 11 January 2017. Retrieved 26 June 2024.
"Pembrolizumab (Keytruda) Checkpoint Inhibitor". U.S. Food and Drug Administration. 25 October 2016. Archived from the original on 11 January 2017. Retrieved 26 June 2024. This article incorporates text from this source, which is in the public domain.

asco.org

"FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy". ASCO. 12 June 2018. Archived from the original on 12 January 2020. Retrieved 13 June 2018.

bbc.co.uk

Roberts M (7 November 2022). "NHS reaches deal for life-saving breast-cancer drug". BBC News Online. Archived from the original on 11 November 2022. Retrieved 11 November 2022.

canada.ca

"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Archived from the original on 20 February 2020. Retrieved 7 April 2024.

cancer.gov

"Checkpoint Inhibitor Use Changed for Bladder Cancer". National Cancer Institute. 26 July 2018. Archived from the original on 18 March 2021. Retrieved 12 November 2019.
"pembrolizumab". National Cancer Institute. 2 February 2011. Archived from the original on 23 October 2020. Retrieved 3 December 2020.

cancernetwork.com

"FDA Approves Anti-PD-1 Drug for Advanced Melanoma". CancerNetwork. 4 September 2014. Archived from the original on 10 January 2016. Retrieved 7 September 2014.

clinicaltrials.gov

Clinical trial number NCT01295827 for "Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)" at ClinicalTrials.gov
National Cancer Institute (NCI) (13 May 2023). A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (Report). ClinicalTrials.gov. Archived from the original on 19 June 2024. Retrieved 19 June 2024.
Clinical trial number NCT02752074 for "A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)" at ClinicalTrials.gov
Clinical trial number NCT03914612 for "A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer" at ClinicalTrials.gov

doi.org

Redman JM, Gibney GT, Atkins MB (February 2016). "Advances in immunotherapy for melanoma". BMC Medicine. 14 (1): 20. doi:10.1186/s12916-016-0571-0. PMC 4744430. PMID 26850630.
Fuereder T (20 June 2016). "Immunotherapy for head and neck squamous cell carcinoma". Memo. 9 (2): 66–69. doi:10.1007/s12254-016-0270-8. PMC 4923082. PMID 27429658.
Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
Vachhani P, Chen H (September 2016). "Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date". OncoTargets and Therapy. 9: 5855–5866. doi:10.2147/ott.s97746. PMC 5045223. PMID 27713639.
Nasser NJ, Gorenberg M, Agbarya A (November 2020). "First line Immunotherapy for Non-Small Cell Lung Cancer". Pharmaceuticals. 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686.
Photopoulos J (23 September 2020). "The future of tissue-agnostic drugs". Nature. 585 (7826): S16–S18. Bibcode:2020Natur.585S..16P. doi:10.1038/d41586-020-02679-6. S2CID 221884179.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. (August 2021). "Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma". The New England Journal of Medicine. 385 (8): 683–694. doi:10.1056/NEJMoa2106391. PMID 34407342.
Linardou H, Gogas H (July 2016). "Toxicity management of immunotherapy for patients with metastatic melanoma". Annals of Translational Medicine. 4 (14): 272. doi:10.21037/atm.2016.07.10. PMC 4971373. PMID 27563659.
Francisco LM, Sage PT, Sharpe AH (July 2010). "The PD-1 pathway in tolerance and autoimmunity". Immunological Reviews. 236: 219–242. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.
Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. (April 2015). "Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications". Oncoimmunology. 4 (4): e1008814. doi:10.1080/2162402x.2015.1008814. PMC 4485728. PMID 26137403.
Riley JL (May 2009). "PD-1 signaling in primary T cells". Immunological Reviews. 229 (1): 114–125. doi:10.1111/j.1600-065X.2009.00767.x. PMC 3424066. PMID 19426218.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–264. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. (August 2010). "Improved survival with ipilimumab in patients with metastatic melanoma". The New England Journal of Medicine. 363 (8): 711–723. doi:10.1056/nejmoa1003466. PMC 3549297. PMID 20525992.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. (July 2013). "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma". The New England Journal of Medicine. 369 (2): 134–144. doi:10.1056/nejmoa1305133. PMC 4126516. PMID 23724846.
Ledford H (24 May 2017). "Tissue-independent cancer drug gets fast-track approval from US regulator". Nature. doi:10.1038/nature.2017.22054. Archived from the original on 12 November 2020. Retrieved 17 June 2017.
Schmid P, Cortés J, Dent R, Pusztai L, McArthur HL, Kuemmel S, et al. (2019). "KEYNOTE-522: phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)". Annals of Oncology. 30 (5): v853–v854. doi:10.1093/annonc/mdz394.003.
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. (June 2016). "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma". The New England Journal of Medicine. 374 (26): 2542–2552. doi:10.1056/NEJMoa1603702. PMC 4927341. PMID 27093365.
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. (July 2017). "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade". Science. 357 (6349): 409–413. Bibcode:2017Sci...357..409L. doi:10.1126/science.aan6733. PMC 5576142. PMID 28596308.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. (July 2021). "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50". Journal of Clinical Oncology. 39 (21): 2339–2349. doi:10.1200/JCO.21.00174. PMC 8280089. PMID 33872070.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. (March 2023). "Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer". The New England Journal of Medicine. 388 (23): 2159–2170. doi:10.1056/NEJMoa2302312. PMC 10351614. PMID 36972022. S2CID 257765751.
"Precision medicine meets cancer vaccines". Nature Medicine. 29 (6): 1287. June 2023. doi:10.1038/s41591-023-02432-2. PMID 37328586. S2CID 259184146.
Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G (March 2023). "Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects". Vaccines. 11 (3): 636. doi:10.3390/vaccines11030636. PMC 10057252. PMID 36992220.

drugs.com

"Pembrolizumab (Keytruda) Use During Pregnancy". Drugs.com. 24 September 2019. Archived from the original on 14 June 2020. Retrieved 10 January 2020.
"Pembrolizumab Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 14 June 2020. Retrieved 15 July 2019.

england.nhs.uk

"NHS strikes deal for potentially life-saving breast cancer drug". NHS England. 8 November 2022. Archived from the original on 20 June 2024. Retrieved 20 June 2024.

europa.eu

ema.europa.eu

"Keytruda EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 24 May 2020. Retrieved 30 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Assessment report: Keytruda. Procedure No. EMEA/H/C/003820/0000" (PDF). European Medicines Agency (EMA). 21 May 2015. Archived (PDF) from the original on 14 June 2018. Retrieved 5 November 2016.
"Keytruda index page at EMA". European Medicines Agency (EMA). Archived from the original on 20 June 2018. Retrieved 10 November 2016.

fda.gov

"FDA approves pembrolizumab combination for the first-line treatment of cervical cancer". U.S. Food and Drug Administration. 13 October 2021. Archived from the original on 13 October 2021. Retrieved 15 October 2021.
"FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer". U.S. Food and Drug Administration. 11 August 2021. Archived from the original on 28 July 2021. Retrieved 28 July 2021.
"FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer" (Press release). U.S. Food and Drug Administration. 29 June 2020. Archived from the original on 29 June 2020. Retrieved 29 June 2020. This article incorporates text from this source, which is in the public domain.
"Pembrolizumab (Keytruda) for classical Hodgkin lymphoma". U.S. Food and Drug Administration. 14 March 2017. Archived from the original on 12 January 2020. Retrieved 12 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for advanced esophageal squamous cell cancer". U.S. Food and Drug Administration (Press release). 30 July 2019. Archived from the original on 12 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication". U.S. Food and Drug Administration (Press release). 23 May 2017. Archived from the original on 23 April 2019. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for esophageal or GEJ carcinoma". U.S. Food and Drug Administration. 22 March 2021. Archived from the original on 23 March 2021. Retrieved 22 March 2021. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer". U.S. Food and Drug Administration. 5 May 2021. Archived from the original on 5 May 2021. Retrieved 5 May 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for high-risk early-stage triple-negative b". U.S. Food and Drug Administration. 27 July 2021. Archived from the original on 27 July 2021. Retrieved 27 July 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC". U.S. Food and Drug Administration. 3 December 2021. Archived from the original on 3 December 2021. Retrieved 4 December 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma". U.S. Food and Drug Administration. 17 November 2021. Archived from the original on 6 October 2023. Retrieved 2 October 2023.
"FDA approves pembrolizumab for advanced endometrial carcinoma". U.S. Food and Drug Administration. 21 March 2022. Archived from the original on 22 March 2022. Retrieved 21 March 2022.
"FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer". U.S. Food and Drug Administration. 26 January 2023. Archived from the original on 26 January 2023. Retrieved 27 January 2023. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab with chemotherapy for biliary tract cancer". U.S. Food & Drug Administration (FDA). 1 November 2023. Archived from the original on 12 November 2023. Retrieved 12 November 2023.
"FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage". U.S. Food and Drug Administration. 12 January 2024. Archived from the original on 26 June 2024. Retrieved 9 March 2024. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma". U.S. Food and Drug Administration. 17 June 2024. Archived from the original on 18 June 2024. Retrieved 18 June 2024. This article incorporates text from this source, which is in the public domain.
Bala S, Nair A, Lemery S, Marcus L, Goldberg KB, Pazdur R (30 May 2017). "FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript". U.S. Food and Drug Administration. Archived from the original on 12 January 2020. Retrieved 12 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves Keytruda for advanced melanoma" (Press release). U.S. Food and Drug Administration. 4 September 2014. Archived from the original on 27 December 2015. Retrieved 24 December 2015. This article incorporates text from this source, which is in the public domain.
"FDA approves Keytruda for advanced non-small cell lung cancer" (Press release). U.S. Food and Drug Administration. 2 October 2015. Archived from the original on 8 November 2015. Retrieved 12 January 2020. This article incorporates text from this source, which is in the public domain.
"Pembrolizumab injection". U.S. Food and Drug Administration. 5 October 2015. Archived from the original on 11 January 2017. Retrieved 26 June 2024.
"pembrolizumab (Keytruda)" (Press release). U.S. Food and Drug Administration. 5 August 2016. Archived from the original on 16 December 2019. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"Pembrolizumab (Keytruda) Checkpoint Inhibitor". U.S. Food and Drug Administration. 25 October 2016. Archived from the original on 11 January 2017. Retrieved 26 June 2024. This article incorporates text from this source, which is in the public domain.
"FDA approves first cancer treatment for any solid tumor with a specific genetic feature". U.S. Food and Drug Administration (Press release). 23 May 2017. Archived from the original on 12 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for metastatic small cell lung cancer". U.S. Food and Drug Administration (Press release). 17 June 2019. Archived from the original on 6 April 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL". U.S. Food and Drug Administration (Press release). 13 June 2018. Archived from the original on 12 January 2020. Retrieved 16 June 2018. This article incorporates text from this source, which is in the public domain.
"FDA updates prescribing information for Keytruda and Tecentriq". U.S. Food and Drug Administration (Press release). 16 August 2018. Archived from the original on 22 December 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma". U.S. Food and Drug Administration (Press release). 9 November 2018. Archived from the original on 12 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for adjuvant treatment of melanoma". U.S. Food and Drug Administration (Press release). 15 February 2019. Archived from the original on 12 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma". U.S. Food and Drug Administration (Press release). 10 June 2019. Archived from the original on 16 December 2019. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for adults and children with TMB-H solid tumors". U.S. Food and Drug Administration. 17 June 2020. Archived from the original on 15 March 2021. Retrieved 19 June 2020.

accessdata.fda.gov

"Accelerated approval notice: BLA 125514/S-14" (PDF). U.S. Food and Drug Administration. 23 May 2017. Archived (PDF) from the original on 28 August 2021. Retrieved 17 June 2017. This article incorporates text from this source, which is in the public domain.

fiercepharma.com

"Amgen slaps record-breaking $178K price on rare leukemia drug Blincyto". 18 December 2014. Archived from the original on 1 April 2016. Retrieved 29 April 2016.

forbes.com

Shaywitz D (26 July 2017). "The Startling History Behind Merck's New Cancer Blockbuster". Forbes. Archived from the original on 26 July 2017. Retrieved 26 July 2017.
Timmerman L (2 June 2015). "ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate". Forbes. Archived from the original on 8 November 2020. Retrieved 8 September 2017.

handle.net

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

harvard.edu

ui.adsabs.harvard.edu

Photopoulos J (23 September 2020). "The future of tissue-agnostic drugs". Nature. 585 (7826): S16–S18. Bibcode:2020Natur.585S..16P. doi:10.1038/d41586-020-02679-6. S2CID 221884179.
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. (July 2017). "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade". Science. 357 (6349): 409–413. Bibcode:2017Sci...357..409L. doi:10.1126/science.aan6733. PMC 5576142. PMID 28596308.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Regulatory Decision Summary for Keytruda". Health Canada. 6 February 2024. Archived from the original on 2 April 2024. Retrieved 2 April 2024.

inventorsdigest.com

"Inventors of the Year". Inventors Digest. 19 December 2016. Archived from the original on 28 October 2020. Retrieved 8 May 2017.

managedcaremag.com

Adams KT (24 July 2015). "Cancer Immunotherapies--and Their Cost--Take Center Stage at ASCO's 2015 Annual Meeting". Managed Care Magazine Online. Archived from the original on 13 December 2017. Retrieved 5 November 2016.

medicines.org.uk

"Keytruda 50 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 7 April 2020. Archived from the original on 13 December 2017. Retrieved 30 April 2020.
"Keytruda 50 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 25 November 2019. Archived from the original on 13 December 2017. Retrieved 10 January 2020.

medpagetoday.com

Jenkins K (5 May 2016). "Keytruda Impresses in Triple-Negative Breast Cancer". MedPage Today. Archived from the original on 19 December 2016. Retrieved 14 May 2016.

merck.com

"FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy". Merck (Press release). 2 October 2015. Archived from the original on 26 June 2024. Retrieved 26 June 2024.

nature.com

Ledford H (24 May 2017). "Tissue-independent cancer drug gets fast-track approval from US regulator". Nature. doi:10.1038/nature.2017.22054. Archived from the original on 12 November 2020. Retrieved 17 June 2017.

neoleukin.com

investor.neoleukin.com

"Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with Keytruda (pembrolizumab)" (Press release). Neoleukin Therapeutics. Archived from the original on 10 January 2022. Retrieved 10 January 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Redman JM, Gibney GT, Atkins MB (February 2016). "Advances in immunotherapy for melanoma". BMC Medicine. 14 (1): 20. doi:10.1186/s12916-016-0571-0. PMC 4744430. PMID 26850630.
Fuereder T (20 June 2016). "Immunotherapy for head and neck squamous cell carcinoma". Memo. 9 (2): 66–69. doi:10.1007/s12254-016-0270-8. PMC 4923082. PMID 27429658.
Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
Vachhani P, Chen H (September 2016). "Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date". OncoTargets and Therapy. 9: 5855–5866. doi:10.2147/ott.s97746. PMC 5045223. PMID 27713639.
Nasser NJ, Gorenberg M, Agbarya A (November 2020). "First line Immunotherapy for Non-Small Cell Lung Cancer". Pharmaceuticals. 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. (August 2021). "Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma". The New England Journal of Medicine. 385 (8): 683–694. doi:10.1056/NEJMoa2106391. PMID 34407342.
Linardou H, Gogas H (July 2016). "Toxicity management of immunotherapy for patients with metastatic melanoma". Annals of Translational Medicine. 4 (14): 272. doi:10.21037/atm.2016.07.10. PMC 4971373. PMID 27563659.
Francisco LM, Sage PT, Sharpe AH (July 2010). "The PD-1 pathway in tolerance and autoimmunity". Immunological Reviews. 236: 219–242. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.
Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. (April 2015). "Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications". Oncoimmunology. 4 (4): e1008814. doi:10.1080/2162402x.2015.1008814. PMC 4485728. PMID 26137403.
Riley JL (May 2009). "PD-1 signaling in primary T cells". Immunological Reviews. 229 (1): 114–125. doi:10.1111/j.1600-065X.2009.00767.x. PMC 3424066. PMID 19426218.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–264. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. (August 2010). "Improved survival with ipilimumab in patients with metastatic melanoma". The New England Journal of Medicine. 363 (8): 711–723. doi:10.1056/nejmoa1003466. PMC 3549297. PMID 20525992.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. (July 2013). "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma". The New England Journal of Medicine. 369 (2): 134–144. doi:10.1056/nejmoa1305133. PMC 4126516. PMID 23724846.
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. (June 2016). "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma". The New England Journal of Medicine. 374 (26): 2542–2552. doi:10.1056/NEJMoa1603702. PMC 4927341. PMID 27093365.
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. (July 2017). "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade". Science. 357 (6349): 409–413. Bibcode:2017Sci...357..409L. doi:10.1126/science.aan6733. PMC 5576142. PMID 28596308.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. (July 2021). "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50". Journal of Clinical Oncology. 39 (21): 2339–2349. doi:10.1200/JCO.21.00174. PMC 8280089. PMID 33872070.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. (March 2023). "Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer". The New England Journal of Medicine. 388 (23): 2159–2170. doi:10.1056/NEJMoa2302312. PMC 10351614. PMID 36972022. S2CID 257765751.
"Precision medicine meets cancer vaccines". Nature Medicine. 29 (6): 1287. June 2023. doi:10.1038/s41591-023-02432-2. PMID 37328586. S2CID 259184146.
Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G (March 2023). "Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects". Vaccines. 11 (3): 636. doi:10.3390/vaccines11030636. PMC 10057252. PMID 36992220.

ncbi.nlm.nih.gov

Redman JM, Gibney GT, Atkins MB (February 2016). "Advances in immunotherapy for melanoma". BMC Medicine. 14 (1): 20. doi:10.1186/s12916-016-0571-0. PMC 4744430. PMID 26850630.
Fuereder T (20 June 2016). "Immunotherapy for head and neck squamous cell carcinoma". Memo. 9 (2): 66–69. doi:10.1007/s12254-016-0270-8. PMC 4923082. PMID 27429658.
Vachhani P, Chen H (September 2016). "Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date". OncoTargets and Therapy. 9: 5855–5866. doi:10.2147/ott.s97746. PMC 5045223. PMID 27713639.
Nasser NJ, Gorenberg M, Agbarya A (November 2020). "First line Immunotherapy for Non-Small Cell Lung Cancer". Pharmaceuticals. 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686.
Linardou H, Gogas H (July 2016). "Toxicity management of immunotherapy for patients with metastatic melanoma". Annals of Translational Medicine. 4 (14): 272. doi:10.21037/atm.2016.07.10. PMC 4971373. PMID 27563659.
Francisco LM, Sage PT, Sharpe AH (July 2010). "The PD-1 pathway in tolerance and autoimmunity". Immunological Reviews. 236: 219–242. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.
Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. (April 2015). "Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications". Oncoimmunology. 4 (4): e1008814. doi:10.1080/2162402x.2015.1008814. PMC 4485728. PMID 26137403.
Riley JL (May 2009). "PD-1 signaling in primary T cells". Immunological Reviews. 229 (1): 114–125. doi:10.1111/j.1600-065X.2009.00767.x. PMC 3424066. PMID 19426218.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–264. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. (August 2010). "Improved survival with ipilimumab in patients with metastatic melanoma". The New England Journal of Medicine. 363 (8): 711–723. doi:10.1056/nejmoa1003466. PMC 3549297. PMID 20525992.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. (July 2013). "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma". The New England Journal of Medicine. 369 (2): 134–144. doi:10.1056/nejmoa1305133. PMC 4126516. PMID 23724846.
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. (June 2016). "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma". The New England Journal of Medicine. 374 (26): 2542–2552. doi:10.1056/NEJMoa1603702. PMC 4927341. PMID 27093365.
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. (July 2017). "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade". Science. 357 (6349): 409–413. Bibcode:2017Sci...357..409L. doi:10.1126/science.aan6733. PMC 5576142. PMID 28596308.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. (July 2021). "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50". Journal of Clinical Oncology. 39 (21): 2339–2349. doi:10.1200/JCO.21.00174. PMC 8280089. PMID 33872070.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. (March 2023). "Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer". The New England Journal of Medicine. 388 (23): 2159–2170. doi:10.1056/NEJMoa2302312. PMC 10351614. PMID 36972022. S2CID 257765751.
Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G (March 2023). "Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects". Vaccines. 11 (3): 636. doi:10.3390/vaccines11030636. PMC 10057252. PMID 36992220.

dailymed.nlm.nih.gov

"Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". DailyMed. 17 September 2019. Archived from the original on 17 June 2020. Retrieved 10 January 2020.

nytimes.com

Pollack A (29 May 2015). "New Class of Drugs Shows More Promise in Treating Cancer". The New York Times. Archived from the original on 29 May 2015. Retrieved 30 May 2015.

onclive.com

global.onclive.com

Potential Biomarkers Identified for Pembrolizumab in Head and Neck Cancer. July 2016^{[permanent dead link]}

onclive.com

"FDA Approves Pembrolizumab for Head and Neck Cancer". OncLive. 6 August 2016. Archived from the original on 5 December 2021. Retrieved 5 December 2021.

semanticscholar.org

api.semanticscholar.org

Photopoulos J (23 September 2020). "The future of tissue-agnostic drugs". Nature. 585 (7826): S16–S18. Bibcode:2020Natur.585S..16P. doi:10.1038/d41586-020-02679-6. S2CID 221884179.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. (March 2023). "Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer". The New England Journal of Medicine. 388 (23): 2159–2170. doi:10.1056/NEJMoa2302312. PMC 10351614. PMID 36972022. S2CID 257765751.
"Precision medicine meets cancer vaccines". Nature Medicine. 29 (6): 1287. June 2023. doi:10.1038/s41591-023-02432-2. PMID 37328586. S2CID 259184146.

telegraph.co.uk

Roberts L (8 November 2022). "NHS to treat aggressive form of breast cancer with potentially life-saving drug". The Telegraph. Archived from the original on 20 June 2024. Retrieved 20 June 2024.

tga.gov.au

"Keytruda, Microsatellite instability-high cancer". Department of Health and Aged Care, Commonwealth of Australia. Archived from the original on 22 November 2022.
"Keytruda, Oesophageal Cancer". Department of Health and Aged Care, Commonwealth of Australia. Archived from the original on 22 November 2022.
"Keytruda (pembrolizumab) is indicated for the adjuvant treatment of adult and adolescent (12 years and older) patients with Stage IIB, IIC, or III melanoma who have undergone complete resection". Department of Health and Aged Care, Commonwealth of Australia. Archived from the original on 18 March 2023. Retrieved 18 March 2023.
"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 31 March 2024. Retrieved 31 March 2024.

thepharmaletter.com

"Merck & Co and Taiho to co-promote cancer immunotherapy pembrolizumab in Japan". The Pharma Letter. 13 April 2016. Archived from the original on 18 April 2018. Retrieved 10 November 2016.
"Merck & Co updates Keytruda findings at ASCO". The Pharma Letter. 10 June 2016. Archived from the original on 5 November 2016. Retrieved 5 November 2016.

thetranslationalscientist.com

"Unlocking Checkpoint Inhibition". Translational Scientist. 2 March 2016. Archived from the original on 5 November 2018. Retrieved 5 November 2016.

web.archive.org

"Pembrolizumab (Keytruda) Use During Pregnancy". Drugs.com. 24 September 2019. Archived from the original on 14 June 2020. Retrieved 10 January 2020.
"Keytruda, Microsatellite instability-high cancer". Department of Health and Aged Care, Commonwealth of Australia. Archived from the original on 22 November 2022.
"Keytruda, Oesophageal Cancer". Department of Health and Aged Care, Commonwealth of Australia. Archived from the original on 22 November 2022.
"Keytruda (pembrolizumab) is indicated for the adjuvant treatment of adult and adolescent (12 years and older) patients with Stage IIB, IIC, or III melanoma who have undergone complete resection". Department of Health and Aged Care, Commonwealth of Australia. Archived from the original on 18 March 2023. Retrieved 18 March 2023.
"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 31 March 2024. Retrieved 31 March 2024.
"Regulatory Decision Summary for Keytruda". Health Canada. 6 February 2024. Archived from the original on 2 April 2024. Retrieved 2 April 2024.
"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Archived from the original on 20 February 2020. Retrieved 7 April 2024.
"Keytruda 50 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 7 April 2020. Archived from the original on 13 December 2017. Retrieved 30 April 2020.
"Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". DailyMed. 17 September 2019. Archived from the original on 17 June 2020. Retrieved 10 January 2020.
"Keytruda EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 24 May 2020. Retrieved 30 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"FDA approves pembrolizumab combination for the first-line treatment of cervical cancer". U.S. Food and Drug Administration. 13 October 2021. Archived from the original on 13 October 2021. Retrieved 15 October 2021.
"Pembrolizumab Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 14 June 2020. Retrieved 15 July 2019.
"FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer". U.S. Food and Drug Administration. 11 August 2021. Archived from the original on 28 July 2021. Retrieved 28 July 2021.
"FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer" (Press release). U.S. Food and Drug Administration. 29 June 2020. Archived from the original on 29 June 2020. Retrieved 29 June 2020. This article incorporates text from this source, which is in the public domain.
"Keytruda 50 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 25 November 2019. Archived from the original on 13 December 2017. Retrieved 10 January 2020.
"Pembrolizumab (Keytruda) for classical Hodgkin lymphoma". U.S. Food and Drug Administration. 14 March 2017. Archived from the original on 12 January 2020. Retrieved 12 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for advanced esophageal squamous cell cancer". U.S. Food and Drug Administration (Press release). 30 July 2019. Archived from the original on 12 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"Checkpoint Inhibitor Use Changed for Bladder Cancer". National Cancer Institute. 26 July 2018. Archived from the original on 18 March 2021. Retrieved 12 November 2019.
"FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication". U.S. Food and Drug Administration (Press release). 23 May 2017. Archived from the original on 23 April 2019. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for esophageal or GEJ carcinoma". U.S. Food and Drug Administration. 22 March 2021. Archived from the original on 23 March 2021. Retrieved 22 March 2021. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer". U.S. Food and Drug Administration. 5 May 2021. Archived from the original on 5 May 2021. Retrieved 5 May 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for high-risk early-stage triple-negative b". U.S. Food and Drug Administration. 27 July 2021. Archived from the original on 27 July 2021. Retrieved 27 July 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC". U.S. Food and Drug Administration. 3 December 2021. Archived from the original on 3 December 2021. Retrieved 4 December 2021. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma". U.S. Food and Drug Administration. 17 November 2021. Archived from the original on 6 October 2023. Retrieved 2 October 2023.
"FDA approves pembrolizumab for advanced endometrial carcinoma". U.S. Food and Drug Administration. 21 March 2022. Archived from the original on 22 March 2022. Retrieved 21 March 2022.
"FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer". U.S. Food and Drug Administration. 26 January 2023. Archived from the original on 26 January 2023. Retrieved 27 January 2023. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab with chemotherapy for biliary tract cancer". U.S. Food & Drug Administration (FDA). 1 November 2023. Archived from the original on 12 November 2023. Retrieved 12 November 2023.
"FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage". U.S. Food and Drug Administration. 12 January 2024. Archived from the original on 26 June 2024. Retrieved 9 March 2024. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma". U.S. Food and Drug Administration. 17 June 2024. Archived from the original on 18 June 2024. Retrieved 18 June 2024. This article incorporates text from this source, which is in the public domain.
"pembrolizumab". National Cancer Institute. 2 February 2011. Archived from the original on 23 October 2020. Retrieved 3 December 2020.
Bala S, Nair A, Lemery S, Marcus L, Goldberg KB, Pazdur R (30 May 2017). "FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript". U.S. Food and Drug Administration. Archived from the original on 12 January 2020. Retrieved 12 January 2020. This article incorporates text from this source, which is in the public domain.
"Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). AMA ASSN. 27 November 2013. Archived (PDF) from the original on 26 October 2020. Retrieved 5 November 2016.
"Assessment report: Keytruda. Procedure No. EMEA/H/C/003820/0000" (PDF). European Medicines Agency (EMA). 21 May 2015. Archived (PDF) from the original on 14 June 2018. Retrieved 5 November 2016.
"Unlocking Checkpoint Inhibition". Translational Scientist. 2 March 2016. Archived from the original on 5 November 2018. Retrieved 5 November 2016.
"Inventors of the Year". Inventors Digest. 19 December 2016. Archived from the original on 28 October 2020. Retrieved 8 May 2017.
Shaywitz D (26 July 2017). "The Startling History Behind Merck's New Cancer Blockbuster". Forbes. Archived from the original on 26 July 2017. Retrieved 26 July 2017.
"FDA approves Keytruda for advanced melanoma" (Press release). U.S. Food and Drug Administration. 4 September 2014. Archived from the original on 27 December 2015. Retrieved 24 December 2015. This article incorporates text from this source, which is in the public domain.
"FDA Approves Anti-PD-1 Drug for Advanced Melanoma". CancerNetwork. 4 September 2014. Archived from the original on 10 January 2016. Retrieved 7 September 2014.
Pollack A (29 May 2015). "New Class of Drugs Shows More Promise in Treating Cancer". The New York Times. Archived from the original on 29 May 2015. Retrieved 30 May 2015.
"Merck & Co and Taiho to co-promote cancer immunotherapy pembrolizumab in Japan". The Pharma Letter. 13 April 2016. Archived from the original on 18 April 2018. Retrieved 10 November 2016.
"Keytruda index page at EMA". European Medicines Agency (EMA). Archived from the original on 20 June 2018. Retrieved 10 November 2016.
"FDA approves Keytruda for advanced non-small cell lung cancer" (Press release). U.S. Food and Drug Administration. 2 October 2015. Archived from the original on 8 November 2015. Retrieved 12 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy". Merck (Press release). 2 October 2015. Archived from the original on 26 June 2024. Retrieved 26 June 2024.
"pembrolizumab (Keytruda)" (Press release). U.S. Food and Drug Administration. 5 August 2016. Archived from the original on 16 December 2019. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA Approves Pembrolizumab for Head and Neck Cancer". OncLive. 6 August 2016. Archived from the original on 5 December 2021. Retrieved 5 December 2021.
"FDA approves first cancer treatment for any solid tumor with a specific genetic feature". U.S. Food and Drug Administration (Press release). 23 May 2017. Archived from the original on 12 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
Ledford H (24 May 2017). "Tissue-independent cancer drug gets fast-track approval from US regulator". Nature. doi:10.1038/nature.2017.22054. Archived from the original on 12 November 2020. Retrieved 17 June 2017.
"Accelerated approval notice: BLA 125514/S-14" (PDF). U.S. Food and Drug Administration. 23 May 2017. Archived (PDF) from the original on 28 August 2021. Retrieved 17 June 2017. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for metastatic small cell lung cancer". U.S. Food and Drug Administration (Press release). 17 June 2019. Archived from the original on 6 April 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy". ASCO. 12 June 2018. Archived from the original on 12 January 2020. Retrieved 13 June 2018.
"FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL". U.S. Food and Drug Administration (Press release). 13 June 2018. Archived from the original on 12 January 2020. Retrieved 16 June 2018. This article incorporates text from this source, which is in the public domain.
"FDA updates prescribing information for Keytruda and Tecentriq". U.S. Food and Drug Administration (Press release). 16 August 2018. Archived from the original on 22 December 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma". U.S. Food and Drug Administration (Press release). 9 November 2018. Archived from the original on 12 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for adjuvant treatment of melanoma". U.S. Food and Drug Administration (Press release). 15 February 2019. Archived from the original on 12 January 2020. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma". U.S. Food and Drug Administration (Press release). 10 June 2019. Archived from the original on 16 December 2019. Retrieved 10 January 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves pembrolizumab for adults and children with TMB-H solid tumors". U.S. Food and Drug Administration. 17 June 2020. Archived from the original on 15 March 2021. Retrieved 19 June 2020.
National Cancer Institute (NCI) (13 May 2023). A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (Report). ClinicalTrials.gov. Archived from the original on 19 June 2024. Retrieved 19 June 2024.
"Amgen slaps record-breaking $178K price on rare leukemia drug Blincyto". 18 December 2014. Archived from the original on 1 April 2016. Retrieved 29 April 2016.
"NHS strikes deal for potentially life-saving breast cancer drug". NHS England. 8 November 2022. Archived from the original on 20 June 2024. Retrieved 20 June 2024.
Roberts M (7 November 2022). "NHS reaches deal for life-saving breast-cancer drug". BBC News Online. Archived from the original on 11 November 2022. Retrieved 11 November 2022.
Roberts L (8 November 2022). "NHS to treat aggressive form of breast cancer with potentially life-saving drug". The Telegraph. Archived from the original on 20 June 2024. Retrieved 20 June 2024.
Timmerman L (2 June 2015). "ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate". Forbes. Archived from the original on 8 November 2020. Retrieved 8 September 2017.
Adams KT (24 July 2015). "Cancer Immunotherapies--and Their Cost--Take Center Stage at ASCO's 2015 Annual Meeting". Managed Care Magazine Online. Archived from the original on 13 December 2017. Retrieved 5 November 2016.
Jenkins K (5 May 2016). "Keytruda Impresses in Triple-Negative Breast Cancer". MedPage Today. Archived from the original on 19 December 2016. Retrieved 14 May 2016.
"Merck & Co updates Keytruda findings at ASCO". The Pharma Letter. 10 June 2016. Archived from the original on 5 November 2016. Retrieved 5 November 2016.
"Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with Keytruda (pembrolizumab)" (Press release). Neoleukin Therapeutics. Archived from the original on 10 January 2022. Retrieved 10 January 2022.